Biomaterial Database

Outpatient cervical ripening using a sustained-release prostaglandin E2 vaginal insert. 2001

S A Tassone, and C R Pearman, and W F Rayburn

Department of Obstetrics and Gynecology, University of Oklahoma, Health Sciences Center, Oklahoma City.

This clinical trial was undertaken to determine whether a sustained-release prostaglandin E2 vaginal insert could be used for outpatient cervical ripening. A total of 111 patients, with primarily pregnancy-induced hypertension or postdatism, were administered the insert in a simulated outpatient setting. The high rates of regular contractions (23.4%) and of removal of the insert before < 12 hours (27.9%) make its use undesirable outside a hospital.

UI	MeSH Term	Description	Entries
D010045	Outpatients	Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.	Out-patients,Out patients,Out-patient,Outpatient
D010349	Patient Compliance	Voluntary cooperation of the patient in following a prescribed regimen.	Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D011247	Pregnancy	The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	Gestation,Pregnancies
D003692	Delayed-Action Preparations	Dosage forms of a drug that act over a period of time by controlled-release processes or technology.	Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293	Adolescent	A person 13 to 18 years of age.	Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D014590	Uterine Contraction	Contraction of the UTERINE MUSCLE.	Myometrial Contraction,Contraction, Myometrial,Contraction, Uterine,Contractions, Myometrial,Contractions, Uterine,Myometrial Contractions,Uterine Contractions
D014621	Vagina	The genital canal in the female, extending from the UTERUS to the VULVA. (Stedman, 25th ed)	Vaginas

Related Publications

S A Tassone, and C R Pearman, and W F Rayburn

Improved intravaginal controlled-release prostaglandin E2 insert for cervical ripening at term. The Prostaglandin E2 insert Study Group.

January 1996, The Journal of maternal-fetal medicine,

S A Tassone, and C R Pearman, and W F Rayburn

Cervical ripening with prostaglandin E2 vaginal suppositories.

May 1984, Obstetrics and gynecology,

S A Tassone, and C R Pearman, and W F Rayburn

Outpatient cervical ripening with prostaglandin E2 and estradiol.

February 2002, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians,

S A Tassone, and C R Pearman, and W F Rayburn

Prostaglandin E2 (PGE2) vaginal gel for cervical ripening.

February 1991, European journal of obstetrics, gynecology, and reproductive biology,

S A Tassone, and C R Pearman, and W F Rayburn

Controlled-release prostaglandin E2 pessary and cervical ripening.

September 1990, Lancet (London, England),

S A Tassone, and C R Pearman, and W F Rayburn

Plasma progesterone, dehydroepiandrosterone sulfate and estriol levels during labor induction with a sustained-release prostaglandin E2 vaginal insert.

June 2001, The Journal of maternal-fetal medicine,

S A Tassone, and C R Pearman, and W F Rayburn

Cervical ripening and labor induction with a controlled-release dinoprostone vaginal insert.

April 2000, Obstetrics and gynecology,